Search the Health Library
Get the facts on diseases, conditions, tests and procedures.
I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
I Want to...
Home > News and Publications > JHM Publications > Promise and Progress > Reprogramming Cancer Cells - The Story of Epigenetics
Promise and Progress - New Leukemia Findings
Reprogramming Cancer Cells - The Story of Epigenetics
Issue No. 1
Issue No. 1
New Leukemia Findings
Date: July 16, 2014
Blood, March 2014
Proceedings of the National Academy of Science, November 2013
A new genetically engineered mouse model that mimics a common form of leukemia may help researchers better understand and treat resistant forms of the disease. The mice were bred with mutation of the FLT3 gene, an alteration common in adult and pediatric acute myeloid leukemia. The mouse model will allow researchers, led by leading FLT3 expert Donald Small, M.D., the Kyle Haydock Professor of Oncology and Director of Pediatric Oncology, to explore the full impact of FLT3 mutations, which occur in various regions of the gene. Dr. Small led the team of researchers that cloned the FLT3 gene and linked it to leukemia two decades ago.
In their ongoing research, Dr. Small and team revealed that the region where the FLT3 gene is mutated significantly impacts the aggressiveness of the disease. He believes the mice provide a new platform for dissecting the molecular mechanisms resulting in poor prognosis in AML and for screening drugs that may work against them.
He and his team used the model in a recent study to explore a promising new drug that blocks FLT3. In preliminary laboratory studies, he compared the new drug to other FLT3 inhibitors. The new agent appeared to be more active against all types of FLT3 activating mutations and resistance mutations and also blocked downstream signaling in the FLT3 pathway.
The “Blood” research was funded by Alex’s Lemonade Stand Foundation for Childhood Cancer, the National Institutes of Health’s National Cancer Institute grants CA 90668, CA 70970, and RR 025005, Giant Food Pediatric Cancer Research Fund, and the Pharmacology Analytical Core of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
The Proceedings of the National Academy of Science research was funded by National Institutes of Health grants CA 090668 and CA 070970, the Leukemia & Lymphoma Society, and the Giant Food Pediatric Cancer Research Fund.
Articles in this Issue
- Headline Makers - Overview
- A Safer Way to Treat Pediatric Brain Cancers
- For Cervical Lesions, Tissue Exam Beats Conventional Blood Tests
- Blood Cells Transformed to Repair Damaged Retina
- Personalized Chemotherapy
- 3D Scans Show whether Treatment is Working
- Alcohol Metabolite Could Increase Cancer Risk in Some People
- Acupuncture, Real or Simulated, Eases Hot Flashes
- New Leukemia Findings
- HPV Oral Cancers and Risk of Infection for Couples
- Molecular Marker of Cancer Drug Response
- Chronic Inflammation Connected to Prostate Cancer
- Fat Versus Brain Cancer
- DNA Damaging Toxins In Food
- Cancer Patients Who Quit Smoking Live Longer
- New Immune Therapy Shows Promise Against Melanoma
- Breathe Easier and Fight Cancer
- Cost-Cutting and Excellent Care Not Mutuallly Exclusive
- The Key to Safe Bone Marrow Transplants Revealed